CoCites: A citation-based method for searching scientific literature

A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer.

Yoshiko Nanki, Hiroyuki Nomura, Naomi Iwasa, Keiko Saotome, Ai Dozen, Tomoko Yoshihama, Takuro Hirano, Shiho Hashimoto, Tatsuyuki Chiyoda, Wataru Yamagami, Fumio Kataoka, Daisuke Aoki. Jpn J Clin Oncol 2021
Times Cited: 1

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.

E Vrdoljak, N Marschner, C Zielinski, J Gligorov, J Cortes, F Puglisi, M Aapro, L Fallowfield, A Fontana, M Inbar, Z Kahan, A Welt, C Lévy, E Brain, X Pivot, C Putzu, A González Martín, S de Ducla, V Easton, G von Minckwitz. Ann Oncol 2016
Times Cited: 21

List of shared articles

Times cited

The use of bevacizumab is correlated with improved post-progression survival in advanced recurrent ovarian cancer.
Shintaro Yanazume, Takashi Ushiwaka, Mika Fukuda, Shinichi Togami, Masaki Kamio, Hiroaki Kobayashi. Jpn J Clin Oncol 2021